Pulmonx to Present at the Bank of America Securities 2023 Health Care Conference

Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, will present at the Bank of America Securities 2023 Health Care Conference in Las Vegas on May 9, 2023, at 3:55 PM PT / 6:55 PM ET.

Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, will present at the Bank of America Securities 2023 Health Care Conference in Las Vegas on May 9, 2023, at 3:55 PM PT / 6:55 PM ET. The presentation will be accessible via a live and archived webcast on the company’s website.

Pulmonx is known for its Zephyr® Endobronchial Valve, which treats patients with severe emphysema/COPD. This device has received FDA pre-market approval as a breakthrough device and is available in over 25 countries. With more than 100,000 valves employed, over 25,000 patients have been treated worldwide.

Argus Session date unavailable

-0.09% session move Open Argus

Details

News Market Reaction – LUNG

The recorded move for LUNG in the trading session of this news was -0.09%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2023 Health Care Conference in Las Vegas on Tuesday, May 9, 2023, at 3:55 PM PT / 6:55 PM ET.

A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr^® Endobronchial Valve, Chartis^® Pulmonary Assessment System and StratX^® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Pulmonx^®, Chartis^®, StratX^®, and Zephyr^® are registered trademarks of Pulmonx Corporation.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Pulmonx presenting at the Bank of America Securities 2023 Health Care Conference?

Pulmonx is presenting on May 9, 2023, at 3:55 PM PT / 6:55 PM ET.

How can I watch the Pulmonx presentation?

You can watch the presentation live or archived on the Pulmonx website in the Investors section.

What products does Pulmonx offer for lung disease?

Pulmonx offers the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform.

How many Zephyr Valves have been used by Pulmonx?

Over 100,000 Zephyr Valves have been used to treat more than 25,000 patients.

What is the significance of the Zephyr Valve for Pulmonx?

The Zephyr Valve has received FDA pre-market approval as a breakthrough device and is designed for patients with severe emphysema/COPD.